cGAS-STING signalling in cancer: striking a balance with chromosomal instability.
Journal article
Beernaert B. and Parkes EE., (2023), Biochem Soc Trans
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.
Journal article
Fletcher CE. et al, (2022), Mol Cancer, 21
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers.
Journal article
van Vugt MATM. and Parkes EE., (2022), Trends Cancer, 8, 174 - 189
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.
Journal article
Parkes EE. et al, (2022), Br J Cancer, 126, 247 - 258
The tumor microenvironment and immune responses in prostate cancer patients.
Journal article
Kwon JTW. et al, (2021), Endocr Relat Cancer, 28, T95 - T107
Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors.
Conference paper
Harrington K. et al, (2021), CANCER RESEARCH, 81
The clinical and molecular significance associated with STING signaling in breast cancer.
Journal article
Parkes EE. et al, (2021), NPJ Breast Cancer, 7
Development of Immunotherapy Combination Strategies in Cancer.
Journal article
Yap TA. et al, (2021), Cancer Discov, 11, 1368 - 1397
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.
Journal article
Li J. et al, (2021), Cancer Discov, 11, 1212 - 1227
Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.
Journal article
Willenbrock F. et al, (2021), Br J Cancer, 124, 581 - 586
Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
Journal article
Philippou Y. et al, (2020), Br J Cancer, 123, 1089 - 1100
The clinical and molecular significance associated with STING signaling in estrogen receptor-positive early breast cancer
Preprint
Parkes EE. et al, (2020)
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial
Journal article
Sharma P. et al, (2019), Journal of Clinical Oncology, 37, 3484 - 3492
Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study
Journal article
McCain RS. et al, (2019), Cancer Causes & Control, 31, 1 - 11
Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.
Journal article
Turkington RC. et al, (2019), Gut, 68, 1918 - 1927
DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy
Journal article
Gilmore E. et al, (2019), JOURNAL OF ONCOLOGY, 2019
Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application
Journal article
Lightbody G. et al, (2019), BRIEFINGS IN BIOINFORMATICS, 20, 1795 - 1811
Topoisomerase II inhibitors induce cGAS-STING dependent inflammation resulting in cytokine induction and immune checkpoint activation
Preprint
Wilkinson RDA. et al, (2019)
Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer
Journal article
Humphries MP. et al, (2018), Journal of Oncology, 2018, 1 - 14
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Journal article
Parkes EE. et al, (2016), Journal of the National Cancer Institute, 109, djw199 - djw199